Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Tyrosine Protein Kise CSK (C Src Kise or Protein Tyrosine Kise CYL or CSK or EC 2.7.10.2) - Overview
Tyrosine Protein Kise CSK (C Src Kise or Protein Tyrosine Kise CYL or CSK or EC 2.7.10.2) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Tyrosine Protein Kise CSK (C Src Kise or Protein Tyrosine Kise CYL or CSK or EC 2.7.10.2) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Tyrosine Protein Kise CSK (C Src Kise or Protein Tyrosine Kise CYL or CSK or EC 2.7.10.2) - Companies Involved in Therapeutics Development
Advenchen Laboratories LLC
Athenex Inc
Bristol-Myers Squibb Co
Pfizer Inc
Pulmatrix Inc
Tyrosine Protein Kise CSK (C Src Kise or Protein Tyrosine Kise CYL or CSK or EC 2.7.10.2) - Drug Profiles
apatinib mesylate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
bosutinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
dasatinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
eCF-506 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures


Number of Products under Development by Stage of Development, H1 2020
Number of Products under Development by Therapy Areas, H1 2020
Number of Products under Development by Top 10 Indications, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Routes of Administration, H1 2020
Number of Products by Stage and Routes of Administration, H1 2020
Number of Products by Molecule Types, H1 2020
Number of Products by Stage and Molecule Types, H1 2020


List of Tables


Number of Products under Development by Stage of Development, H1 2020
Number of Products under Development by Therapy Areas, H1 2020
Number of Products under Development by Indications, H1 2020
Number of Products under Development by Indications, H1 2020 (Contd..1), H1 2020
Number of Products under Development by Indications, H1 2020 (Contd..2), H1 2020
Number of Products under Development by Indications, H1 2020 (Contd..3), H1 2020
Number of Products under Development by Indications, H1 2020 (Contd..4), H1 2020
Number of Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Products under Development by Companies, H1 2020 (Contd..2), H1 2020
Products under Development by Companies, H1 2020 (Contd..3), H1 2020
Products under Development by Companies, H1 2020 (Contd..4), H1 2020
Products under Development by Companies, H1 2020 (Contd..5), H1 2020
Products under Development by Companies, H1 2020 (Contd..6), H1 2020
Number of Products under Investigation by Universities/Institutes, H1 2020
Products under Investigation by Universities/Institutes, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Pipeline by Advenchen Laboratories LLC, H1 2020
Pipeline by Athenex Inc, H1 2020
Pipeline by Bristol-Myers Squibb Co, H1 2020
Pipeline by Pfizer Inc, H1 2020
Pipeline by Pulmatrix Inc, H1 2020
Dormant Products, H1 2020
Dormant Products, H1 2020 (Contd..1), H1 2020
Discontinued Products, H1 2020